Apogee Therapeutics (APGE) Capital Expenditures (2024 - 2025)
Apogee Therapeutics (APGE) reported Capital Expenditures of $62000.0 for Q4 2025, up 6300.0% year-over-year from $968.75 in Q4 2024, and down 98.72% on a QoQ basis from $4.9 million in Q2 2025.
Apogee Therapeutics (APGE) has 2 years of Capital Expenditures data on file, last reported at $62000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 6300.0% year-over-year to $62000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (up 346.79% YoY) and the FY2025 annual result came in at $5.1 million, up 346.79% from the prior year.
- Capital Expenditures slipped to $62000.0 in Q4 2025 per APGE's latest filing, from $4.9 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.9 million in Q2 2025 and bottomed at -$1000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Jun 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 751,000.00 |
| Sep 30, 2024 | 751,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 351,000.00 |
| Mar 31, 2024 | 351,000.00 |